<!DOCTYPE html>
<html  lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<script async src="https://www.googletagmanager.com/gtag/js?id=G-273DTKB5QW"></script>
<meta name="description" content="CGMP/QSR/Medical Devices/Adulterated" />
<meta name="dcterms.title" content="Medtronic, Inc. - 617539 - 12/09/2021" />
<meta name="dcterms.creator" content="Center for Devices and Radiological Health" />
<meta name="dcterms.description" content="CGMP/QSR/Medical Devices/Adulterated" />
<meta name="dcterms.publisher" content="FDA" />
<meta name="dcterms.source" content="FDA" />
<meta property="og:site_name" content="U.S. Food and Drug Administration" />
<meta property="og:type" content="Article" />
<meta property="og:url" content="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medtronic-inc-617539-12092021" />
<meta property="og:title" content="Medtronic, Inc. - 617539 - 12/09/2021" />
<meta property="og:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<meta property="og:updated_time" content="Tue, 12/28/2021 - 09:20" />
<meta property="og:street_address" content="710 Medtronic Parkway" />
<meta property="og:locality" content="Minneapolis" />
<meta property="og:region" content="MN" />
<meta property="og:postal_code" content="55432" />
<meta property="og:country_name" content="US" />
<meta property="article:publisher" content="FDA" />
<meta property="article:published_time" content="Wed, 03/19/2025 - 15:19" />
<meta property="article:modified_time" content="Tue, 12/28/2021 - 09:20" />
<meta name="google-site-verification" content="tWxlDhm4ANdksJZPj7TBmHgNoMqZCnecPp0Aa2vC9XA" />
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:site" content="@US_FDA" />
<meta name="twitter:title" content="Medtronic, Inc. - 617539 - 12/09/2021" />
<meta name="twitter:creator" content="@US_FDA" />
<meta name="twitter:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<script type="application/ld+json">{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": "Article",
            "headline": "Medtronic, Inc. - 617539 - 12/09/2021",
            "name": "Medtronic, Inc. - 617539 - 12/09/2021",
            "description": "CGMP/QSR/Medical Devices/Adulterated",
            "image": {
                "@type": "ImageObject",
                "representativeOfPage": "True",
                "url": "/themes/custom/preview/img/FDA-Social-Graphic.png"
            },
            "datePublished": "Wed, 03/19/2025 - 15:19",
            "dateModified": "Tue, 12/28/2021 - 09:20",
            "author": {
                "@type": "Organization",
                "name": "Center for Devices and Radiological Health"
            },
            "publisher": {
                "@type": "Organization",
                "name": "FDA"
            }
        }
    ]
}</script>
<meta property="og:description" content="CGMP/QSR/Medical Devices/Adulterated" />
<meta property="twitter:description" content="CGMP/QSR/Medical Devices/Adulterated" />
<link rel="icon" href="/themes/custom/preview/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medtronic-inc-617539-12092021" />
<link rel="canonical" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medtronic-inc-617539-12092021" />
<link rel="shortlink" href="https://www.fda.gov/node/412189" />
<script src="/files/google_tag/production/google_tag.script.js?t5y79a" defer></script>

    <title>Medtronic, Inc. - 617539 - 12/09/2021 | FDA</title>
    <link rel="stylesheet" media="all" href="/files/css/css_I1lI2DYRy4WvhS49GZC8Z2v9NUFD60djX72-ZNQ0RPY.css?delta=0&amp;language=en&amp;theme=preview&amp;include=eJxNzEsOwjAMRdENBbykKJ9HZeLGJXZA2T2CQWFydUa3NFR2HZF7RfcsWhr9Odgyx045GcIx8GS8aBPNSS7mS7hv4f6YGCtOjjU5Di4Ng34MN1Xv6jA6FT4fo2-vu9YpeAPskjb1" />
<link rel="stylesheet" media="all" href="/files/css/css_hj_HG-FreAYyrzLosS3-54RaarbPLxzHFgHCJpFJLhA.css?delta=1&amp;language=en&amp;theme=preview&amp;include=eJxNzEsOwjAMRdENBbykKJ9HZeLGJXZA2T2CQWFydUa3NFR2HZF7RfcsWhr9Odgyx045GcIx8GS8aBPNSS7mS7hv4f6YGCtOjjU5Di4Ng34MN1Xv6jA6FT4fo2-vu9YpeAPskjb1" />

    <script src="https://script.crazyegg.com/pages/scripts/0024/3700.js" async></script>
<script src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&amp;subagency=FDA&amp;sdor=fda.gov&amp;dclink=true" language="javascript" id="_fed_an_ua_tag"></script>

            <script>window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag("js", new Date());gtag("set", "developer_id.dMDhkMT", true);gtag("config", "G-273DTKB5QW", {"groups":"default","page_placeholder":"PLACEHOLDER_page_location","allow_ad_personalization_signals":false});</script>
        
  </head>
  <body class="role-anonymous path-node page-node-type-warning-letter has-glyphicons">
      <div id="quicklinks" class="sr-only display-on-focus">
        <ul class="list-inline padding-left-3 padding-right-3">
          <li><a href="#main-content" class="btn btn-default margin-top-3" tabindex="1">Skip to main content</a></li>
          <li><a href="#search-form" class="btn btn-default margin-top-3" tabindex="1">Skip to FDA Search</a></li>
          <li><a href="#section-nav" class="btn btn-default margin-top-3" tabindex="1">Skip to in this section menu</a></li>
          <li><a href="#footer" class="btn btn-default margin-top-3" tabindex="1">Skip to footer links</a></li>
        </ul>   
      </div>    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M95XGZW" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
       
  <div class="main-container container-fluid">     <div class="row">
                                                               


	
	<header class="lcds-header container-fluid" role="banner">
		                    
			<div class="row us-masthead">                            

				<div class="usa-banner col-xs-12">

					<img class="usa-banner__us-flag" src="/themes/custom/preview/assets/images/US_Flag.png" alt="U.S. flag" />

					<span>An official website of the United States government</span>

				    <a id="USMenuButton" class="collapsed" role="button" aria-expanded="false" aria-controls="USABannerMenu" href="#" data-toggle="collapse" data-target="#USABannerMenu">Here’s how you know <span class="toggle-indicator"> </span></a>

          			<div class="col-xs-12 collapse usa-banner__menu" id="USABannerMenu" aria-labelledby="USMenuButton">


						<div id="gov-banner" class="row usa-banner-content usa-grid usa-accordion-content" aria-hidden="true">
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-dot-gov.svg" alt="Dot gov" style="width:3em;">
									<div class="usa-media_block-body">
								      <p><strong>The .gov means it’s official.</strong><br>Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.</p>
								    </div>
							      </div>
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-https.svg" alt="SSL" style="width:3em;">
							        <div class="usa-media_block-body">
								         <p><strong>The site is secure.</strong><br> The <strong>https://</strong> ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.</p>
							        </div>
							      </div>
						</div>
					</div>

				</div>
			</div> 			<div class="row fda-masthead">
							<div class="col-xs-4 col-md-8 fda-masthead__fda-logo"> 
					<a href="/" title="FDA Homepage">
            <picture>
              <!-- Set media breakpoint to value equivalent to $screen-md -->
              <source media="(min-width:992px)" srcset="/themes/custom/preview/assets/images/gov-fda-new-white.svg">
              <img src="/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg" height="40px" alt="U.S. Food and Drug Administration logo">
            </picture>
          </a>
       	</div>
				
        <div class="col-xs-8 col-md-4">
        <ul class="fda-masthead__item-list">
            <li>
                <button id="btn-search" class="btn btn-default btn-sm fda-masthead__btn-search" aria-expanded="false" aria-controls="search-form" title="Open search bar">
					<span class="fa fa-search" aria-hidden="true">&nbsp;</span>
			    	<span class="fda-masthead__btn-label">Search</span>
				</button>
            </li>
            <li>
                <button id="menu-btn" class="btn btn-default btn-sm fda-masthead__btn-menu collapsed" href="#primary-nav" data-toggle="collapse" aria-expanded="true">
                    <span class="fa fa-bars" aria-hidden="true">&nbsp;</span>
                    <span class="fda-masthead__btn-label">Menu</span>
                </button>
            </li>
        </ul>
		</div>
							
						<form class="fda-masthead__search sr-only" id="search-form" aria-hidden="true" role="search" action="/search" method="GET" accept-charset="UTF-8">
							<div class="search-popover" id="search-popover">
								<div class="input-group pull-right" id="search-group">
									<label class="sr-only" for="search-query">Search FDA</label>
									
									<input class="form-control search-input" tabindex="-1" id="search-query" name="s" aria-autocomplete="list" aria-haspopup="true" title="Enter the terms you wish to search for." placeholder="Search FDA"  type="text" /> 
									
									<span class="input-group-btn" id="input-group-btn">
										
										<button type="submit" type="button" class="btn btn-danger search-btn" id="search-btn" tabindex="-1" title="Search"><span class="fa fa-search" aria-hidden="true"><span class="sr-only">Submit search</span></span></button>

									</span>

								</div>
							</div>
																				
						</form>					

			</div> 
		<nav id="primary-nav" class="lcds-primary-nav row collapse">					<div class="col-md-5 col-lg-4">
						<section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
							<h2 class="lcds-primary-nav__group-heading">Featured</h2>
							<ul class="lcds-primary-nav__list lcds-primary-nav__list--featured">
								<li class="lcds-primary-nav__list-item"><a href="https://www.safetyreporting.hhs.gov/smarthub#/" title="Report a Problem with an FDA Regulated Product">Report a Product Problem</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/about-fda/contact-fda">Contact FDA</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/regulatory-information/search-fda-guidance-documents">FDA Guidance Documents</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/safety/recalls-market-withdrawals-safety-alerts">Recalls, Market Withdrawals and Safety Alerts</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/news-events/newsroom/press-announcements">Press Announcements</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters">Warning Letters</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/advisory-committees">Advisory Committees</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/fda-en-espanol">En Espa&#241ol</a></li>
							</ul>
						</section>
					</div>

					<div class="col-md-7 col-lg-8">
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Products</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/food">Food</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/drugs">Drugs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/medical-devices">Medical Devices</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/radiation-emitting-products">Radiation-Emitting Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/vaccines-blood-biologics">Vaccines, Blood, and Biologics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/animal-veterinary">Animal and Veterinary</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/cosmetics">Cosmetics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/tobacco-products">Tobacco Products</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Topics</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/about-fda">About FDA</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/combination-products">Combination Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/regulatory-information">Regulatory Information</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/safety">Safety</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/emergency-preparedness-and-response">Emergency Preparedness</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/international-programs">International Programs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/news-events">News and Events</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/training-and-continuing-education">Training and Continuing Education</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations">Inspections and Compliance</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/science-research">Science and Research</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Information For</h2>
            <ul class="lcds-primary-nav__list">
	            <li class="lcds-primary-nav__list-item"><a href="/consumers">Consumers</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/patients">Patients</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/industry">Industry</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/health-professionals">Health Professionals</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/federal-state-local-tribal-and-territorial-officials">Federal, State and Local Officials</a></li>
            </ul>
          </section>
					</div>
	      </nav>
    </header>

<div class="col-xs-12">
	<div data-drupal-messages-fallback class="hidden"></div>

</div>

                              
                                                                     <section id="block-entityviewcontent" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

<a class="lcds-button--expandable collapsed hidden-md hidden-lg" data-toggle="collapse" href="#section-nav" >In this section<span class="visible-sm-inline-block">:

                Warning Letters
    
    </span>
</a>

<nav id="section-nav" class="lcds-card lcds-section-nav lcds-section-nav hidden-md hidden-lg collapse">

    <ul class="lcds-section-nav__list">

      <li>

              <a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters" title="Warning Letters" class="lcds-section-nav__section-link lcds-section-nav__link lcds-section-nav__parent-link visible-xs-block visible-sm-block">
                                        Warning Letters
                    </a>

                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_5 js-view-dom-id-445340ea3a0feeda5e455951cf4fc2473503066b9266c1a6da5def411d80fbd9">
  
    
      
  
      <div>
  
  <ul class="lcds-section-nav__section-link__active lcds-section-nav__list">

          <li><a href="/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters" class="lcds-section-nav__link">About Warning and Close-Out Letters</a></li>
    
  </ul>

</div>


  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_2 js-view-dom-id-622e12e7c2c15e2c38e9fd13ab8fb8722a558945eb0318046df3707460afe547">
  
    
      
  
          </div>
</div>


      </li>

    </ul>

</nav>

  </section>

<section id="block-entityviewcontent-15" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
    <ol class="lcds-breadcrumb visible-md visible-lg">
          <li >
                  <a href="/">Home</a>
              </li>
          <li >
                  <a href="/inspections-compliance-enforcement-and-criminal-investigations">Inspections, Compliance, Enforcement, and Criminal Investigations</a>
              </li>
          <li >
                  <a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities">Compliance Actions and Activities</a>
              </li>
          <li >
                  <a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters">Warning Letters</a>
              </li>
          <li >
                  <a class="current-link">Medtronic, Inc. - 617539 - 12/09/2021</a>
              </li>
      </ol>




<ol class="lcds-breadcrumb visible-sm visible-xs">
  <li>
    <a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters" title="Warning Letters">
     Warning Letters
    </a>
  </li>
</ol>

  </section>






                                
      <main>

                                 <article id="main-content" class="article main-content container-fluid" role="article">
          
                                                                <header class="row content-header">
                         <section id="block-entityviewcontent-8" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
<div class="col-sm-12 col-md-8 col-md-offset-2">

        <p class="content-type-label text-center">WARNING LETTER</p>
      <h1 class="text-center content-title">Medtronic, Inc.
            
      <span class="font-family-sans">
                  MARCS-CMS 617539 —           <time datetime="2021-12-09T00:00:00Z">December 09, 2021</time>
</span></h1>


    
 
</div>

  </section>






                      </header>
                              
                                                          
                              <aside class="col-md-2" role="complementary">
                  <section id="block-entityviewcontent-3" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

        <div class="region region-">
    <p class="text-center "><a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters" class="btn btn-default"><i class="fa fa-arrow-circle-left" aria-hidden="true"></i> More Warning Letters</a></p>

     
    <nav id="section-nav"class="lcds-card lcds-section-nav lcds-section-nav--side hidden-xs hidden-sm">
      <ul class="lcds-section-nav__list lcds-section-nav--side__list">
        <li>

                    <a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters" title="Warning Letters" class="lcds-section-nav__link lcds-section-nav--side__link lcds-section-nav__parent-link lcds-section-nav--side__parent-link">
                                        Warning Letters
                      </a>

          
                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_4 js-view-dom-id-5f660de3b2cb46da21cbb47d9dca498849db71570b924cad5fb2d52acc535826">
  
    
      
  
      <div class="item-list">
  
  <ul class="lcds-section-nav__active lcds-section-nav__list lcds-section-nav--side__list">

          <li><a href="/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters" class="lcds-section-nav__link lcds-section-nav--side__link">About Warning and Close-Out Letters</a></li>
    
  </ul>

</div>


  
          </div>
</div>


        </li>
      </ul> 
    </nav>
  </div>    

  </section>


                </aside>
              
                                                          
              <div class="col-md-8" role="main">

                            
                            
                            
                            
                                              
  
 

                 

  <hr>
 

<div class="inset-column">
  <dl class="lcds-description-list--grid">

              <dt class="cell-1_1">Delivery Method:</dt> 
        <dd class="cell-2_1">VIA Electronic Mail
                                                                                                                                                                                                                                                                                                                                                                                                                              </dd>
      
      
              <dt class="cell-1_3">Product:</dt> 
        <dd class="cell-2_3">Medical Devices                          
            
            
            
            
            
            
            
             
            
            
            
              
            
            
            </dd>
      
          </dl>
  </div>            


<hr>

<div class="row inset-column">
  <div class="col-xs-12 col-md-6">
    <dl class="">

        <dt>Recipient:</dt>

                      <dd>
  <div class="field field--name-field-recipient-name field--type-string field--label-above">
    <div class="field--label">Recipient Name</div>
              <div class="field--item">Geoff S. Martha</div>
          </div>
</dd>
                                <dd>
  <div class="field field--name-field-recipient-title field--type-string field--label-above">
    <div class="field--label">Recipient Title</div>
              <div class="field--item">Chief Executive Officer</div>
          </div>
</dd>
          
            <dd>Medtronic, Inc.</dd>

          
                      <dd><p class="address" translate="no"><span class="address-line1">710 Medtronic Parkway</span><br>
<span class="locality">Minneapolis</span>, <span class="administrative-area">MN</span> <span class="postal-code">55432</span><br>
<span class="country">United States</span></p></dd>
          
          
            
            <dd><!-- Loop this field. For FDA Office content type. Display the Other contact channel is a dd span with an icon-->

    <dd><span class="fa fa-envelope" aria-hidden="true"></span><a href="mailto:Geoff.martha@medtronic.com"> Geoff.martha@medtronic.com</a></dd>
</dd>
          
    </dl>
  </div>            

       <div class="col-xs-12 col-md-6">
    <dl class="">
          
          <dt>Issuing Office:</dt>
        
         
          <dd>Center for Devices and Radiological Health</dd>
        
         
          <dd><p class="address" translate="no"><span class="country">United States</span></p></dd>
        
        
        
        
        
    </dl>
    <dl class=""> 
      
    </dl>
  </div>  
      
</div>

 

 

<hr>

<p class="text-align-center"><strong>WARNING LETTER </strong></p>

<p class="text-align-center"><strong>CMS 617539</strong></p>

<p>December 9, 2021<br>
&nbsp;</p>

<p>Dear Mr. Martha:</p>

<p>During an inspection of your firm located in Northridge, California, on June 7, 2021 through July&nbsp;7, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that&nbsp;your firm manufactures the MiniMed 600 series insulin infusion pumps, and software and remote&nbsp;controllers used in conjunction with the Paradigm and MiniMed series insulin infusion pumps. &nbsp;Under&nbsp;section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(h)], these&nbsp;products are devices because they are intended for use in the diagnosis of disease or other&nbsp;conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the&nbsp;structure or any function of the body.</p>

<p>This inspection revealed the devices are adulterated within the meaning of section 501(h) of the&nbsp;Act [21 U.S.C. § 351(h)] in that the methods used in, or the facilities or controls used for, the&nbsp;manufacture, packing, storage, or installation are not in conformity with the current good&nbsp;manufacturing practice requirements of the Quality System regulation found at Title 21, Code of&nbsp;Federal Regulations (CFR), Part 820. &nbsp;You may find the Act and FDA’s regulations through links in the FDA’s home page <a href="//www.fda.gov.">www.fda.gov.</a> &nbsp;We received your responses from Sean Salmon, Executive Vice President and President Diabetes Operating Unit, and Chirag Tilara, Vice President,&nbsp;Quality Management Representative, dated July 28, September 3, October 8, November 5, and December&nbsp;3, 2021, concerning our investigator’s observations noted on the Form FDA 483, Inspectional&nbsp;Observations, that was issued to your firm on July 7, 2021. &nbsp;We have considered these responses in&nbsp;relation to our observations noted during the inspection, which include, but are not limited to,&nbsp;the following:</p>

<p><strong>1. &nbsp;You failed to adequately establish procedures for corrective and preventive action, as required&nbsp;by 21 CFR 820.100(a).</strong></p>

<p>a. &nbsp;Specifically, in June 2016, your firm initiated CAPA&nbsp;<strong>(b)(4)</strong>#299677 to address anincrease in complaints of damaged retainer rings (clear retainer rings) in the MiniMed 600 Series&nbsp;Insulin Infusion Pumps. &nbsp;Your investigation determined the device failures were caused by the&nbsp;<strong>(b)(4)</strong> retainer ring, which in turn caused a <strong>(b)(4)</strong>. &nbsp;A damaged&nbsp;retainer ring may result in the over or under-delivery of insulin, which may lead to hypoglycemia&nbsp;or hyperglycemia.Beginning August 2019, your firm began releasing the re-designed pumps (which were manufactured&nbsp;with a black retainer ring) for distribution. &nbsp;You began notifying customers of retainer ring&nbsp;failures in November 2019. &nbsp;FDA determined that there was a reasonable probability that the use of,&nbsp;or exposure to, the pumps manufactured with the clear retainer ring would cause serious adverse&nbsp;health consequences, including severe hypoglycemia which can result in loss of consciousness,&nbsp;seizure; severe hyperglycemia which can result in diabetic ketoacidosis or hyperosmolar&nbsp;hyperglycemic state, metabolic abnormalities; or death and classified the recall (RES84430) as&nbsp;class 1. &nbsp;However, your firm failed to adequately implement procedures for corrective and&nbsp;preventive action (CAPA) in that you failed to adequately analyze all sources of quality data,&nbsp;failed to identify actions needed to correct nonconforming product, and you did not appropriately&nbsp;verify or validate the change to your device to ensure corrective and preventive actions taken were&nbsp;effective and did not adversely affect the finished device. &nbsp;While you implemented your procedure,&nbsp;we disagree with your characterization of the risk threshold which led to a conclusion of a lower&nbsp;risk than was appropriate. &nbsp;For example:</p>

<p>i. &nbsp; Your CAPA <em>System</em> procedure (SOP114-01DOC, Effective Date 5/19/2015, Version L) requires your&nbsp;firm to determine whether distributed product is potentially affected by a nonconformance and to&nbsp;conduct additional risk assessment activities per the <em>Product Risk Management Process</em> (SOP104- 08,&nbsp;Version W). &nbsp;In June 2016, your firm conducted a <strong>(b)(4)</strong>16-1051, Version A) which, per your Product Risk Management Process, outlines affected product&nbsp;in the field, and is a risk assessment and health hazard evaluation for informing field corrective&nbsp;action (“FCA”) decisions. &nbsp;Based on FDA’s own evaluation of risk, your outcomes of risk assessment&nbsp;do not appear to be appropriate. &nbsp;In conducting your <strong>(b)(4)</strong> you did not accurately calculate the risk&nbsp;associated with the failed retainer rings in the MiniMed 600 Series Insulin Infusion Pumps because&nbsp;your risk calculation formula underestimated the probability of occurrence of harm, resulting in&nbsp;your firm classifying the risk as “<strong>(b)(4)</strong>” (zone <strong>(b)(4)</strong>)&nbsp;<strong>(b)(4)</strong>” (zone <strong>(b)(4)</strong>). &nbsp;Consequently, your firm did not&nbsp;initiate a correction or removal to address the defective devices from the field because per your&nbsp;<strong>(b)(4)</strong>, the risk of serious adverse health consequences was “improbable.”</p>

<p>ii. &nbsp; In March 2021, your firm revised your <em>Product Risk Management Process</em> (SOP104-08, Version&nbsp;AL), which updated the formula for risk calculation; however, this also did not result in accurate&nbsp;risk calculation. &nbsp;The updated formula uses the “total shipment of affected product” which again&nbsp;underestimates the probability of occurrence because the number of products shipped includes&nbsp;devices not in use by patients (e.g., devices shipped to distributors that have not yet been&nbsp;distributed to customers). Further, the update also changed the parameters on the risk evaluation&nbsp;matrix, increasing the <strong>(b)(4)</strong> parameters (zones <strong>(b)(4)</strong>) and <strong>(b)(4)</strong> parameters (zone <strong>(b)(4)</strong>), thus requiring a higher occurrence for a harm to be classified as “<strong>(b)(4)</strong>”&nbsp;(zone <strong>(b)(4)</strong>). &nbsp;In June 2021 your firm again repeated the <strong>(b)(4)</strong>, but due to the changes made in your risk&nbsp;evaluation formula and matrix, your firm again classified the risk as “<strong>(b)(4)</strong>” (zone <strong>(b)(4)</strong>&nbsp;(zone <strong>(b)(4)</strong>).</p>

<p>iii. &nbsp; Your firm did not identify the actions needed to control devices already in distribution. As previously discussed, your firm’s justification in June 2016 for not initiating a recall was&nbsp;based on your firm’s underestimated risk calculation. &nbsp;Per your Product Review Board Decision Form,&nbsp;dated September 2, 2016 and signed by your VP/President IIM Diabetes on October 3, 2016, while your&nbsp;firm initially planned to develop a customer communication regarding the reservoir retainer ring&nbsp;issue, the decision to not initiate a customer communication was based on “<strong>(b)(4)</strong>.” &nbsp;Your firm then <strong>(b)(4)</strong> and <strong>(b)(4)</strong>, each time using&nbsp;the <strong>(b)(4)</strong> and each time <strong>(b)(4)</strong>; your firm consequently did not initiate a recall until November 20, 2019. &nbsp;From initiation of&nbsp;CAPA <strong>(b)(4)</strong>#299677 in June 2016 to November 20, 2019, the date you initiated the recall, you received&nbsp;over 74,000 retainer ring complaints, with over 57,000 of those reported to FDA as MDRs.</p>

<p>iv. &nbsp; After you initiated the recall of the MiniMed 600 Series Insulin Infusion Pumps on November&nbsp;20, 2019, your firm further failed to implement changes in your methods and procedures needed to&nbsp;correct and prevent the recurrence of quality problems. &nbsp;Your recall consisted of a customer&nbsp;notification informing customers with affected insulin pumps to examine their devices for retainer&nbsp;ring damage and to contact Medtronic for a replacement pump if damage was noted; if no damage was&nbsp;noted by the customer, your&nbsp;notification instructed customers to continue using the device and to examine the retainer ring if&nbsp;the device was dropped or bumped. &nbsp;Thus, after redesigning the retainer ring to prevent further&nbsp;risk, you failed to adequately remove the pumps containing the older, less robust ring from the&nbsp;market.</p>

<p>v. &nbsp; Your firm failed to verify and/or validate the corrective and preventive actions to ensure the&nbsp;action taken was effective to prevent recurrence of the nonconformance and did not adversely affect&nbsp;the finished device. &nbsp;Your firm began releasing the re-designed pump with the black retainer ring&nbsp;beginning August 2019 and closed CAPA <strong>(b)(4)</strong>#299677 as effective on October 2, 2020. Per your CAPA&nbsp;effectiveness plan, your firm compared the complaint rate of the newly released pumps <strong>(b)(4)</strong> to the complaint rate of the previous pump design with the clear retainer ring <strong>(b)(4)</strong>…” &nbsp;You concluded the&nbsp;effectiveness criteria were met because the complaint rate for the re-designed pumps was <strong>(b)(4)&nbsp;</strong>while the complaint rate for the previous design was <strong>(b)(4)</strong>. &nbsp;However, you received 322 complaints&nbsp;during the <strong>(b)(4)</strong> effectiveness check period (<strong>(b)(4)</strong> to <strong>(b)(4)</strong>), and as of May 25, 2021, you had&nbsp;received a total of <strong>(b)(4)</strong> complaints of defective black retainer rings. &nbsp;You did not re-evaluate the&nbsp;effectiveness of your corrective and preventive actions to determine whether CAPA <strong>(b)(4)</strong>#299677 should&nbsp;be re-evaluated.</p>

<p>b. &nbsp;Specifically, your firm initiated CAPA <strong>(b)(4)</strong>#401464 on June 29, 2018, to address a cybersecurity&nbsp;vulnerability with the remote controllers used with your Medtronic MiniMed 508 Insulin Infusion&nbsp;Pump and your MiniMed Paradigm Insulin Infusion Pumps. &nbsp;The identified cybersecurity vulnerability&nbsp;revealed unauthorized individuals could <strong>(b)(4)</strong>.” &nbsp;The root cause&nbsp;investigation in CAPA <strong>(b)(4)</strong>#401464 indicated the “<strong>(b)(4)</strong>.” &nbsp;In evaluating the risk of patient harm, your firm&nbsp;determined the lack of <strong>(b)(4)</strong> that could lead to delivery of <strong>(b)(4)</strong> could result in&nbsp;catastrophic harm to patients. &nbsp;Per your CAPA <strong>(b)(4)</strong>#401464, to address the root cause of the lack of&nbsp;cyber security requirements in the design, all current and future Medtronic Diabetes software&nbsp;products would be evaluated for encryption security requirements. &nbsp;Your firm also discontinued the&nbsp;manufacture and distribution of the&nbsp;Paradigm Pump products and scrapped remaining inventory of the remote controllers; however, these&nbsp;corrective actions did not address the devices in the field. &nbsp;While your firm initiated a recall of&nbsp;15,787 remote controllers shipped to customers in the previous four years, you have distributed&nbsp;over <strong>(b)(4)</strong> remote controllers since its release in 1999, and you did not notify all customers of&nbsp;this safety issue.</p>

<p>We have reviewed your responses and conclude that they are not adequate because you have not yet&nbsp;provided evidence of implementation for all corrections and corrective actions. We acknowledge your&nbsp;firm has committed to replacing MiniMed 600 Series Insulin Infusion Pumps with the clear retainer&nbsp;ring for all US customers, regardless of warranty status, and will retrieve all Medtronic MiniMed&nbsp;remote controllers from active users, and opened CAPA 539888 in order to track completion of your&nbsp;proposed corrective actions.</p>

<p>You stated you have updated relevant procedures, including but not limited to the risk management&nbsp;procedures, including <em>Product Risk Management Process</em> (SOP104- 08DOC), <em>Risk Management Post&nbsp;Production Procedure</em> (DOP104-068DOC), your recall procedure, <em>Diabetes FCA Program Governance&nbsp;</em>(10578148DOC), to address observation 1 on the FDA 483. You also state you will no longer use a&nbsp;device’s warranty status as a factor in determining the scope of recalls associated with the risk&nbsp;patient harm.&nbsp;Additionally, you state you have updated the <em>Medtronic Internal Message Guide</em> to characterize the&nbsp;field action as a recall to US customers, and opened CAPA 539942 to investigate reports of black&nbsp;retainer ring damage “in light of complaints that have been received.”</p>

<p>We acknowledge that you provided a copy of Engineering Report; <em>NGP 6015265-020 Retainer Ring Damage&nbsp;Investigation</em>, Version B in which you conclude that no manufacturing or design non-conformance was&nbsp;identified. However, you also stated that you have opened CAPA <strong>(b)(4)</strong>#539942 to further investigate&nbsp;damaged retainer rings and that activity is still ongoing.</p>

<p>You have also provided DOP104-068DOC, <em>Risk Management Post Production Procedure</em>, Revision U. This&nbsp;procedure is not adequate. &nbsp;You have <strong>(b)(4)</strong> for the <strong>(b)(4)</strong> “Medtronic MiniMed believes the&nbsp;<strong>(b)(4)</strong> is common&nbsp;practice in the industry”, however you have not provided adequate justification to demonstrate that&nbsp;it is appropriate for your risk calculation. &nbsp;For example, on pg. 200 of “Appendix B_1 of 2”&nbsp;provided in your response dated July 28, 2021 you provided the number of MiniMed 600 Series pumps&nbsp;with clear&nbsp;retainer rings shipped to the field as of February 28, 2021. &nbsp;There is a large difference between&nbsp;the number of products shipped (<strong>(b)(4)</strong>) and number of products actually in use in the field&nbsp;(<strong>(b)(4)</strong>% of product shipped). &nbsp;It is unclear to us if the difference was due to the&nbsp;number of devices currently with distributors. &nbsp;If that is not the case, using the number of&nbsp;products shipped (including devices that are not in use by patients) could under- estimate the&nbsp;probability of occurrence of hazardous situations, even after subtracting products currently with&nbsp;distributors.</p>

<p>In addition, you started <strong>(b)(4)</strong> in <strong>(b)(4)</strong> but did not&nbsp;<strong>(b)(4)</strong> (SOP104-08DOC, Revision AP), stating that the one-year&nbsp;delay was “<strong>(b)(4)</strong>”, however you should not have delayed implementing the <strong>(b)(4)</strong>&nbsp;method. &nbsp;You further attempted to justify your interpretation of the <strong>(b)(4)</strong> in your July 2021&nbsp;response as follows: “<strong>(b)(4)</strong>, etc.) <strong>(b)(4)</strong>”. &nbsp;However, you have not explained how your <strong>(b)(4)</strong>&nbsp;i.e., that for <strong>(b)(4)</strong>” as the <strong>(b)(4)</strong>, especially when the <strong>(b)(4)</strong>.</p>

<p>Following change in the <strong>(b)(4)</strong> situations, you&nbsp;have also re-evaluated your risk zone classification matrix in March 2021 (Change Order&nbsp;QCH00047208, SOP104-08 DOC, Revision AL), stating that “t<strong>(b)(4)</strong>”, which resulted in changes in classification of risk zones. <strong>(b)(4)</strong>: specifically, “<strong>(b)(4)</strong>&nbsp;from <strong>(b)(4).</strong>&nbsp; In Attachment 1.6 of your response&nbsp;provided on July 28, 2021 you stated that your assessment of suitability of the risk acceptability&nbsp;criteria was conducted based on mortality rates associated with type 1 diabetes, however death is&nbsp;not the only serious consequence for population for which insulin pump therapy is indicated. &nbsp;Other&nbsp;adverse events such as severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) can also present&nbsp;serious harms to users and should be considered in your hazard analysis. &nbsp;Similarly, your&nbsp;justification for the reassignment of risk zones for <strong>(b)(4)</strong> events relies heavily on the above&nbsp;calculation of mortality rates only. Furthermore, you argued that, with the removal of the factor&nbsp;of <strong>(b)(4)</strong> from your <strong>(b)(4)</strong> of <strong>(b)(4)</strong>.” &nbsp;However, the risk calculation for <strong>(b)(4)</strong> and severity of the&nbsp;risk zones are separate issues and should be assessed separately; addressing the risk calculation&nbsp;does not justify changing the risk zone classification to maintain the overall risk levels. &nbsp;You&nbsp;have not provided adequate information to support that your revised risk zones are clinically&nbsp;acceptable because they appear to be based only on mortality rates, and not all the adverse events&nbsp;that can occur in the intended use population.</p>

<p>In your response, you should explain how your mortality-based risk calculation is appropriate to&nbsp;address all health risks especially as it led to a down-classification of the risk severity, and&nbsp;update your risk zone classifications if necessary. Finally, in your November 5, 2021 update you&nbsp;stated that you evaluated the Issue Impact Assessments (IIAs) initiated in the last <strong>(b)(4)</strong> and&nbsp;identified 20 IIAs that require remediation to reflect the <strong>(b)(4)</strong> per&nbsp;DOP104-068DOC, <strong>(b)(4)</strong> that is planned to be complete by <strong>(b)(4)</strong>. However, as it is&nbsp;unclear if your revised procedure is adequate and because this corrective action is not yet&nbsp;complete, we cannot evaluate the adequacy at this time.</p>

<p>In summary, your corrective actions are still in process, and you have not yet conducted&nbsp;effectiveness checks to ensure the updated procedures and required employee training &nbsp;will prevent&nbsp;reoccurrence of the identified deficiencies. &nbsp;In your November 5, 2021 update you stated that you&nbsp;completed a retrospective review of CAPA effectiveness criteria and of CAPA effectiveness&nbsp;monitoring thresholds but 38 CAPAs were identified as requiring remediation and/or clarification&nbsp;and 14 CAPAs were identified as requiring a new complaint monitoring plan. &nbsp;You should remediate&nbsp;those CAPAs using an adequate risk analysis and provide a summary of your review and remediation&nbsp;efforts.</p>

<p><strong>2. &nbsp;You failed to review, evaluate, and investigate complaints involving the possible failure of a&nbsp;device to meet any of its specifications, as required by 21 CFR 820.198(c).</strong></p>

<p>a. &nbsp;Your firm failed to investigate over 800 complaints of defective black retainer rings. In June&nbsp;2016, your firm initiated CAPA <strong>(b)(4)</strong>#299677 to address an increase in complaints of damaged retainer&nbsp;rings in the MiniMed 600 Series Insulin Infusion Pumps; as part of the CAPA investigation, your&nbsp;firm determined the retainer ring required re-design, and you changed the retainer ring from a&nbsp;clear <strong>(b)(4)</strong> ring to a black <strong>(b)(4)</strong> ring. &nbsp;You began&nbsp;releasing the re-designed pump with black retainer ring in August 2019, and you closed CAPA&nbsp;<strong>(b)(4)</strong>#299677 as effective October 2020. &nbsp;From December 2019 to May 2021, you received 887 complaints&nbsp;of defective black retainer rings; in 772 of the 887 complaints your firm referenced CAPA <strong>(b)(4)</strong>#299677&nbsp;as the “Formal Investigation</p>

<p>Reference Number” even though this CAPA was an investigation of the previous clear retainer ring&nbsp;design. &nbsp;For example:</p>

<p>i.&nbsp; On January 21, 2020, you received a complaint (CASE-2020-00056605) from a customer&nbsp;reporting a crack on their insulin pump reservoir compartment, and damage to the retainer ring. &nbsp;Your product analysis on the returned device confirmed the device had a “partially broken retainer,&nbsp;cracked reservoir tube lip, missing reservoir tube lip O-ring, and broken reservoir tube lip.” &nbsp;On&nbsp;April 24, 2020, you determined no formal investigation was necessary due to existing/previous&nbsp;formal investigation and referenced CAPA <strong>(b)(4)</strong>#299677. &nbsp;You closed this complaint on April 24, 2020.</p>

<p>ii.&nbsp; On February 20, 2020, you received a complaint (CASE-2020-00139368) from a customer&nbsp;reporting they experience hyperglycemia, with blood glucose levels of 450 mg/dL. &nbsp;The customer&nbsp;stated that the lip ring was missing. &nbsp;Your product analysis on the returned device confirmed the&nbsp;device was missing the reservoir retainer ring and the reservoir tube lip O-ring, and the reservoir&nbsp;would not stay locked in place due to the missing retainer. &nbsp;On May 8, 2020, you determined no&nbsp;formal investigation was necessary due to existing/previous formal investigation and referenced&nbsp;CAPA <strong>(b)(4)</strong>#299677. You closed this complaint on May 8, 2020.</p>

<p>iii.&nbsp; On April 7, 2020, you received a complaint (CASE-2020-00260639) from a customer&nbsp;experiencing a high blood glucose level of 434 mg/dL. &nbsp;The customer reported that the retainer ring&nbsp;was loose, and the reservoir did not lock into place when inserted into the pump. &nbsp;Your product&nbsp;analysis on the returned device confirmed a broken retainer and missing reservoir tube O- ring, and&nbsp;the reservoir did not lock into place. &nbsp;On June 5, 2020, you determined no formal investigation was&nbsp;necessary due to existing/previous formal investigation and referenced CAPA <strong>(b)(4)</strong>#299677. &nbsp;You closed&nbsp;this complaint on June 6, 2020.</p>

<p>b. &nbsp;Your firm failed to adequately investigate a complaint in which the customer reported <strong>(b)(4)</strong> of insulin that were not programmed by the customer. You received a complaint on December&nbsp;25, 2019 (CASE-2019-00921665) where the customer alleged that their low blood glucose was the&nbsp;result of over-delivery of insulin by their Paradigm Insulin Infusion Pump (Model MMT-715WWS),&nbsp;which per the <strong>(b)(4)</strong>, reflected <strong>(b)(4)</strong> that were not programmed by the customer. The&nbsp;device was returned to your firm for analysis and the complaint was escalated to your cybersecurity&nbsp;Incident Response Management Team. Your investigation included a review of the downloaded CareLink data, in which the <strong>(b)(4)</strong> reported by&nbsp;the customer were not reflected. However, your firm’s investigation did not include reviewing the&nbsp;actual pump history to verify the presence of the additional <strong>(b)(4)</strong>. This complaint was closed&nbsp;June 26, 2021 as “the cause of the event cannot be determined, as product analysis found no failure&nbsp;or anomaly in the device.”</p>

<p>c. &nbsp; Your firm failed to adequately investigate complaints of Enlite3 MMT-7020A glucose sensor&nbsp;failures. &nbsp;You received two complaints of sensor failures, both of which were closed as “analysis&nbsp;is not required as this complaint is not reportable, and the sensor lot number is unknown.” &nbsp;However, there is no evidence in either complaint record that technical support attempted to&nbsp;determine the lot numbers when communicating with the complainants, even though your <em>Guides,&nbsp;Troubleshooting, Glucose Sensor</em> procedure (DOP114-691DOC, Revisions AL and AM) requires all service&nbsp;notifications to include a lot or batch number for the product. &nbsp;Furthermore, while your <em>Failure&nbsp;Analysis-Glucose Sensor Products</em> procedure (DOP830DOC, Version V) indicates expired sensors are not&nbsp;required to be analyzed, it is not clear how your firm determined the sensors were expired when&nbsp;neither complaint record lists an expiration date, and you failed to determine the lot or batch&nbsp;number of the returned sensors. &nbsp;Last, your <em>Failure Analysis-Glucose Sensor Products</em> procedure does&nbsp;not include MDR reportability as a requirement for sensor analysis.</p>

<p>d. &nbsp;Your firm failed to adequately investigate reported issues with your CareLink software that&nbsp;your firm manufactures; this software uses information transmitted from insulin infusion pumps and&nbsp;glucose meters to create reports intended to assist users with diabetes management. &nbsp;Of the 25&nbsp;complaints reviewed during our inspection, your firm documented “software error unknown” in 20 of&nbsp;the complaints; however, there is no evidence in your complaint records that technical support&nbsp;attempted to determine the version of software used by the device in order to conduct an&nbsp;investigation. &nbsp;During the inspection, your VP of Quality Assurance explained to our investigator&nbsp;that all versions of the software are maintained and could be analyzed to investigate the reported&nbsp;software errors.</p>

<p>We have reviewed your responses and acknowledge you have opened CAPA 539889 to track completion of&nbsp;your proposed corrective actions, including updating complaint investigation and post market&nbsp;trending, as well as implementation of an enhanced training program for complaint handling,&nbsp;technical support, and failure analysis personnel. &nbsp;You have also committed to performing a&nbsp;retrospective review of complaint files for the issues identified on the FDA 483, Inspectional&nbsp;Observations.</p>

<p>In your initial response, you acknowledge CAPA <strong>(b)(4)</strong>#299677 should not have been used to justify not&nbsp;investigating complaints of the re-designed insulin infusion pumps, and you recognize complaints of&nbsp;damaged black retainer rings should have been escalated to a new formal investigation; you have&nbsp;opened CAPA 539942 to conduct this formal investigation. &nbsp;However, your response does not address&nbsp;why your firm deemed the original CAPA <strong>(b)(4)</strong>#299677 as adequate justification for not investigating&nbsp;over 800 complaints in the re-designed pump, nor does it address changes made to prevent recurrence&nbsp;of similar events.</p>

<p>Your response indicates you conducted further analysis of complaint CASE-2019-00921665, in which&nbsp;the customer received <strong>(b)(4)</strong> not programmed into the device; in your supplementary&nbsp;investigation, your firm reviewed the downloaded pump history file and found <strong>(b)(4)</strong> of similar&nbsp;size to those recorded in the complaint. &nbsp;Your supplementary investigation concluded the extra&nbsp;<strong>(b)(4)</strong> were not received over <strong>(b)(4)</strong>, which “rules out the possibility of a cyber security incident.” &nbsp;We acknowledge your firm has updated your <em>Failure Analysis</em>, <em>Paradigm</em> (DOP114-858DOC) and <em>Failure&nbsp;Analysis</em>, NGP (DOP114- 888DOC) procedures, and will update failure analyses as warranted; however,&nbsp;your response does not address your firm’s initial limited investigation, nor does it address&nbsp;changes made to prevent recurrence of similar events.</p>

<p>Your response also describes further investigations of the two complaints of Enlite3 MMT- 7020A&nbsp;glucose sensor failures. &nbsp;Per your response, your firm was able to narrow down and/or determine lot&nbsp;numbers of the sensors via patient history and reassessment of complaint files. In your&nbsp;reassessment you conducted a Lot History Review (LHR) and determined for both complaints “there&nbsp;were no process deviations or out of specification test results observed that would have&nbsp;contributed to a sensor performance issues.” &nbsp;We acknowledge you opened CAPA 541992 to investigate&nbsp;methods to reliably investigate and analyze sensors; however, as this corrective action is not yet&nbsp;complete, we cannot evaluate the adequacy at this time.</p>

<p>We also acknowledge your firm committed to implementing a new failure analysis process specific to&nbsp;software complaints, and opened CAPA 541994 to investigate and identify actions needed, and&nbsp;complaints with “software error unknown” will be investigated as part of that CAPA. &nbsp; However, as&nbsp;part of your corrective actions are not yet complete, including your, retrospective complaint&nbsp;review and systemic complaint investigation processes and training, we cannot evaluate the adequacy&nbsp;of your response at this time.</p>

<p>Our inspection also revealed that your insulin infusion pump devices are misbranded under section&nbsp;502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish&nbsp;material or information respecting the device that is required by or under section 519 of the Act,&nbsp;21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. &nbsp;Significant deficiencies&nbsp;include, but are not limited to, the following:</p>

<p><strong>3. &nbsp;Your firm failed to submit a report to FDA no later than 30 calendar days of receiving or&nbsp;otherwise becoming aware of information that reasonably suggests that a marketed device may have&nbsp;caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).</strong></p>

<p>For example, the information included for complaint #CASE-2020-00236012 describes an event in which&nbsp;your firm’s MiniMed Insulin Pump malfunctioned; after using the device the patient exhibited low&nbsp;glucose reading of 36 mg/dL and was treated with food. &nbsp;We believe that the treatment received by&nbsp;the patient was necessitated to preclude permanent impairment of a body function or permanent&nbsp;damage to a body structure. &nbsp;There is no information included in the firm’s complaint file that&nbsp;rules out the device may not have caused or contributed to the referenced serious injury. &nbsp;As such,&nbsp;the referenced complaint meets the definition of a reportable serious injury, as defined in 21 CFR&nbsp;803.3. The firm became aware of the event on March 27, 2020. However, your firm did not submit an&nbsp;MDR to the FDA.</p>

<p>The adequacy of your firm’s response dated July 28, 2021 cannot be determined at this time. &nbsp;The&nbsp;response noted that your firm is implementing systemic corrective actions, including updates to its&nbsp;reportability criteria, a retrospective review of the complaints and staff training. &nbsp;However, your&nbsp;firm did not provide documentation or evidence that all the corrections and corrective actions,&nbsp;including submission of the referenced serious injury MDR, have been implemented and completed as&nbsp;they are still in progress.</p>

<p>The adequacy of your firm’s response dated September 3, 2021 also cannot be determined at this&nbsp;time. &nbsp;Your response provided an update to its planned or newly added corrective actions, including&nbsp;identification and submission of reportable events associated with retainer ring damage complaints,&nbsp;and implementation of late regulatory review process. &nbsp;However, your firm did not provide&nbsp;documentation or evidence that all the corrections and corrective actions, including submission of&nbsp;the referenced serious injury MDR and planned re-evaluation of its reportability criteria, have&nbsp;been implemented and completed as they are still in progress.</p>

<p>The adequacy of your firm’s responses dated October 8, November 5, and December 2, 2021 also cannot&nbsp;be determined at this time. &nbsp;Your responses provided an update to the planned corrective actions. &nbsp;You provided your new MDR Training Program. &nbsp;However, you also report that training of personnel&nbsp;will not be completed until <strong>(b)(4)</strong>. You also provided <em>D00603958 MDR Decision Alignment with Risk Management Remediation Plan for&nbsp;Diabetes</em>. &nbsp;It is unclear if this plan incorporates an adequate risk analysis (see review under item&nbsp;#1) and you state that your planned actions will not be completed until <strong>(b)(4)</strong>. You did not&nbsp;provide documentation or evidence that all the corrections and corrective actions, including&nbsp;submission of the referenced serious injury MDR and planned re-evaluation of its reportability&nbsp;criteria, have been implemented and completed as they are still in progress.</p>

<p><strong>4. &nbsp;Your firm failed to submit a report to FDA no later than 30 calendar days after the day that&nbsp;the firm received or otherwise became aware of information, from any source, that reasonably&nbsp;suggests that a device that the firm markets has malfunctioned and this device or a similar device&nbsp;that it markets would be likely to cause or contribute to a death or serious injury, if the&nbsp;malfunction were to recur, as required by 21 CFR 803.50(a)(2).</strong></p>

<p>For example, the information included for Complaints #CASE-2018-00270399 and #CASE-2018-00437534&nbsp;reasonably suggests that your firm’s insulin pump malfunctioned (e.g. broken or missing retainer&nbsp;ring) while in use. &nbsp;The same malfunction is the subject of the recall Z-0956-2020 for the same&nbsp;device. &nbsp;Per the 1995 Preamble, a malfunction is reportable if the manufacturer takes, or would be&nbsp;required to take, an action under section 518 or 519(g) of the FD&amp;C as a result of the malfunction&nbsp;of the device or other similar devices {60 FR 63578, 63585 (Dec. 11, 1995)}. Please note that the&nbsp;preamble reference is section 519(f), but the appropriate designation for the section is now&nbsp;section 519(g) due to amendments to the FD&amp;C Act. &nbsp;There is no information included for the&nbsp;complaint files that justifies that the malfunction would not be likely to cause or contribute to a&nbsp;death or serious injury, if it were to recur. &nbsp;As such, your firm should have submitted within the&nbsp;required timeframes, an MDR for each MDR reportable event subject of the referenced complaints. &nbsp;The corresponding MDRs 2032227-2021-157630 and 2032227-2021-157620 were received by FDA beyond the&nbsp;required 30 calendar days timeframe.</p>

<p>The adequacy of your firm’s response dated July 28, 2021 cannot be determined at this time. &nbsp;The&nbsp;response noted that your firm is implementing systemic corrective actions, including updates to its&nbsp;reportability criteria, a retrospective review of the complaints and staff training. However, your&nbsp;firm did not provide documentation or evidence that all the corrections and corrective actions,&nbsp;including the planned assessment of its reportability criteria, have been implemented and completed&nbsp;as they are still in progress.</p>

<p>The adequacy of your firm’s response dated September 3, 2021 also cannot be determined at this&nbsp;time. &nbsp;Your response provided an update to its planned or newly added corrective actions, including&nbsp;identification and submission of reportable events associated with retainer ring damage complaints,&nbsp;and implementation of late regulatory review process. &nbsp;However, your firm did not provide&nbsp;documentation or evidence that all the corrections and corrective actions, including the planned&nbsp;re-evaluation of its reportability criteria, have been implemented and completed as they are still&nbsp;in progress.</p>

<p>The adequacy of your firm’s responses dated October 8, November 5, and December 2, 2021 also cannot&nbsp;be determined at this time. &nbsp;Your response provided an update to the planned corrective actions. &nbsp;You provided your new MDR Training Program. &nbsp;However, you also report that training of personnel&nbsp;will not be completed until <strong>(b)(4)</strong>.&nbsp; You also provided <em>D00603958 MDR Decision Alignment with Risk Management Remediation Plan for&nbsp;Diabetes</em>. &nbsp;It is unclear if this plan incorporates an adequate risk analysis (see review under item&nbsp;#1) and you state that your planned actions will not be completed until <strong>(b)(4)</strong>.&nbsp; You did not&nbsp;provide documentation or evidence that all the corrections and corrective actions, including&nbsp;submission of the referenced serious injury MDR and planned re-evaluation of its reportability&nbsp;criteria, have been implemented and completed as they are still in progress.</p>

<p>This letter notifies you of our findings and provides you an opportunity to address the above&nbsp;deficiencies. &nbsp;Your firm should investigate and determine the causes of any deficiencies, and take&nbsp;prompt actions to correct the deficiencies and bring the products into compliance. Failure to&nbsp;promptly correct these deficiencies may result in regulatory action being initiated by the FDA&nbsp;without further notice. &nbsp;These actions include, but are not limited to, seizure, injunction, and&nbsp;civil money penalties. &nbsp;Additionally, premarket approval applications for Class III devices to&nbsp;which the Quality System regulation deficiencies are reasonably related will not be approved until&nbsp;the deficiencies have been corrected. &nbsp;Also, should FDA determine that your devices do not meet&nbsp;requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.&nbsp;More information on processes for persons denied a CFG can be found at:&nbsp;<a href="/regulatory-information/search-fda-guidance-documents/process-request-review-fdas-decision-not-issue-certain-export-certificates-devices">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-request-review-fdas-decision-not-issue-certain-export-certificates-devices</a>. If you believe that your&nbsp;products are not in violation of the FD&amp;C Act and FDA regulations, please provide us with your&nbsp;reasoning and any supporting information for our consideration within fifteen business days.</p>

<p>You should schedule a teleconference with FDA to further discuss your response to this Warning&nbsp;Letter, particularly in response to your revised risk assessment (please see item 1 above) in more&nbsp;detail. Please notify FDA in writing within fifteen business days from the date you receive this&nbsp;letter of the specific steps your firm has taken to correct the noted Quality System and MDR&nbsp;reporting deficiencies, as well as an explanation of how your firm plans to prevent these deficiencies, or similar deficiencies, from occurring again. &nbsp;Include documentation of the&nbsp;corrections and/or corrective actions (which must address systemic problems) that your firm has&nbsp;taken. &nbsp;If your firm’s planned corrections and/or corrective actions will occur over time, please&nbsp;include a timetable for implementation of those activities. &nbsp;If corrections and/or corrective&nbsp;actions cannot be completed within fifteen business days, state the reason for the delay and the&nbsp;time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive&nbsp;and address all deficiencies included in this Warning Letter.</p>

<p>Your response should be sent to: US Food and Drug Administration, Division 3/West, Office of&nbsp;Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please&nbsp;identify your response with CMS Case #617539. &nbsp;If you have questions about the contents of this&nbsp;letter, please contact Compliance Officer Jamie M. Bumpas at 214-253-5336 or via email at Jamie.bumpas@fda.hhs.gov.</p>

<p>Finally, you should know that this letter is not intended to be an all-inclusive list of the&nbsp;deficiencies at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with&nbsp;applicable laws and regulations administered by FDA. &nbsp;The specific deficiencies noted in this&nbsp;letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be&nbsp;symptomatic of serious problems in your firm’s manufacturing and quality management systems. &nbsp;Your&nbsp;firm should investigate and determine the causes of the deficiencies, and take prompt actions to&nbsp;correct the deficiencies and bring the products into compliance.</p>

<p><br>
Sincerely,</p>

<p>/S/<br>
Shari J. Shambaugh<br>
Program Division Director<br>
Office of Medical Device &amp; Radiological Health<br>
West/Division 3</p>

<p>/S/</p>

<p>Timothy T. Stenzel, M.D., Ph.D.<br>
Director<br>
OHT 7: Office of In Vitro Diagnostics and<br>
Radiological Health<br>
Office of Product Evaluation and Quality<br>
Center for Devices and Radiological Health</p>

<p><br>
Cc:<br>
Sean Salmon, Executive Vice President &amp; President<br>
Diabetes Operating Unit<br>
Medtronic, Inc.<br>
Sean.salmon@medtronic.com</p>

<p>Chirag Tilara, Vice President, Quality<br>
Medtronic, Inc.<br>
Chirag.m.tilara@medtronic.com<br>
&nbsp;</p>


<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->



              
                                            
              
            </div>

                                                  
                          <aside class="col-md-2" role="complementary">
                <section id="block-entityviewcontent-4" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

        <div class="region region-">
  <aside class="lcds-card lcds-card--border-top">
    <ul role="menu" class="lcds-description-list">
      
                            


























  <li role="menuitem" class="node-current-date lcds-description-list__item">
    <div>
      <h2 class="lcds-description-list__item-heading">Content current as of:</h2>
      <p class="lcds-description-list__item-text"><time datetime="2021-12-28T09:20:00Z">12/28/2021</time>
</p>
    </div>
  </li>
               
                
<li role="menuitem" class="lcds-description-list__item">  
	<div>
		
		 <h2 class="lcds-description-list__item-heading">Regulated Product(s)</h2>
		 <ul role="menu" class="lcds-metadata-list">
						  <li role="menuitem">Medical Devices</li>
			  			     			  						              
			
			
			
			
			
			
			
			
					</ul>
	 
			     
						       

			  
						  

			  
						 
	</div>
</li>   

    </ul>

  </aside>
</div>


  </section>


              </aside>
            
                 </article>        
      </main>

    </div>  </div>
<div id="fda-survey-comments"></div>
<script src=https://touchpoints.app.cloud.gov/touchpoints/0eb673d9.js async></script>
<button class="btn btn-primary btn-vertical" id="survey-btn">Feedback</button>
<script src=https://touchpoints.app.cloud.gov/touchpoints/d45bb814.js async=""></script>
                <div class="region region-subscribe">
    <section id="block-entityviewcontent-5" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

  </section>


  </div>

  
      <footer id="footer" class="lcds-footer container-fluid">
        
    <div class="row lcds-footer__primary">
    <nav class="text-center">
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/about-website/fdagov-archive" >FDA Archive</a></li>
          <li><a href="/about-fda" >About FDA</a></li>
          <li><a href="/about-fda/about-website/internet-accessibility" >Accessibility</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/visitor-information" >Visitor Information</a> </li>
          <li><a href="/about-fda/about-website/website-policies" >Website Policies / Privacy</a></li>
          <li><a href="/about-fda/jobs-and-training-fda/no-fear-act" >No FEAR Act</a></li>
          <li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure Policy</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/regulatory-information/freedom-information" title="Freedom of Information Act">FOIA</a></li>
          <li><a href="https://www.hhs.gov/" title="Health and Human Services" target="_blank">HHS.gov</a></li>
          <li><a href="https://www.usa.gov/" target="_blank">USA.gov</a></li>
        </ul>
      </div>
    </nav>
  </div>
    <div class="row lcds-footer__secondary">
    <div class="col-sm-12 col-md-6 col-lg-4 lcds-footer__social-links">
      <a href="/about-fda/contact-fda" class="btn btn-default btn-md">Contact FDA</a>
      <a href="https://www.facebook.com/FDA" title="Follow FDA on Facebook" class="no-disclaimer"> 
        <span class="fa fa-facebook fa-2x" aria-hidden="true">
          <span class="sr-only">Follow FDA on Facebook</span> 
        </span>
      </a>
      <a href="https://x.com/US_FDA" title="Follow FDA on X" class="no-disclaimer">
        <svg class="icon-svg-inline fa-2x" aria-hidden="true">
          <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter">
        </svg>
        <span class="sr-only">Follow FDA on X</span>
      </a>
      <a href="https://instagram.com/FDA" title="Follow FDA on Instagram" class="no-disclaimer">
        <span class="fa fa-instagram fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on Instagram</span>
        </span>
      </a>
      <br class='visible-xs-inline'/>
      <a href="https://www.linkedin.com/company/fda/" title="Follow FDA on LinkedIn" class="no-disclaimer">
        <span class="fa fa-linkedin fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on LinkedIn</span>
        </span>
      </a>
      <a href="https://youtube.com/@US_FDA" title="View FDA videos on YouTube" class="no-disclaimer">
        <span class="fa fa-youtube fa-2x" aria-hidden="true"> 
          <span class="sr-only">View FDA videos on YouTube</span>
        </span>
      </a>
      <a href="/about-fda/contact-fda/subscribe-podcasts-and-news-feeds" title="Subscribe to FDA RSS feeds">
        <span class="fa fa-rss fa-2x" aria-hidden="true">
          <span class="sr-only">Subscribe to FDA RSS feeds</span>
        </span>
      </a>
    </div>
    <a href="/" title="FDA Homepage">
        <div class="visible-lg-block col-lg-4 text-center">
          <img src="/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg" height="60px" alt="Food and Drug Administration Logo">
        </div>
    </a>
    <div class="col-sm-12 col-md-6 col-lg-4 text-center lcds-footer__contact-number">
      <span class="fa fa-phone" aria-hidden="true"> </span> 
     <span class="sr-only">Contact Number</span>
      1-888-INFO-FDA (1-888-463-6332)
    </div>
  </div>
  
      <!--END WEBSITE FEEDBACK SNIPPET-->
  

    </footer>
    <a href="" id="btn-top" class="btn btn-primary btn-top"><span class="sr-only">Back to </span>Top</a>
  

  </div>

    
    <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/412189","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"fda_ckeditor_enhancements":{"basePath":"modules\/custom\/fda_ckeditor_enhancements"},"google_analytics":{"account":"G-273DTKB5QW","trackOutbound":true,"trackMailto":true,"trackTel":true,"trackDownload":true,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip"},"bootstrap":{"forms_has_error_value_toggle":1,"modal_animation":1,"modal_backdrop":"true","modal_focus_input":1,"modal_keyboard":1,"modal_select_text":1,"modal_show":1,"modal_size":"","popover_enabled":1,"popover_animation":1,"popover_auto_close":1,"popover_container":"body","popover_content":"","popover_delay":"0","popover_html":0,"popover_placement":"right","popover_selector":"","popover_title":"","popover_trigger":"click"},"ajax":[],"user":{"uid":0,"permissionsHash":"1b1b521ce0efd787b9481ef00f514b542eb396217a4d74c357d2ecd6b6b52a2d"}}</script>
<script src="/files/js/js_6wBZHfpF3KVtBs6ZtLrAw5oAvps3vbyTaoe7yxCXDtU.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=preview&amp;include=eJxdjtEKwjAMRX9oo74I_k3J0hiLXROSMJlfL1Ms4uM9JOdeFuFGGTq0PSp64j8wqdFW6ZG4yQJtdrSq4dMiEh4GmlRUNrLpWiDjnUoNsUz9Bh1ppR6eAFGsVOk5hA-738QCpdDnSVZt9ThPR5Pn8-nyA8cCNHjuxDxAAX1Lvnlo59H4Ai47WJ8"></script>

  </body>
</html>
